Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 15, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RIGEL PHARMACEUTICALS INC
Report date May 15, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,000 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 5,750 · Balance 7,000 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 20, 2026 00:48 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002530 · form4.xml · nonDerivative · entry 1 Frohlich Mark W · CIK 0001420482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $18.95 | $0.00 |
DisclosureSEC source: 0000905148-25-001931 · form4.xml · derivative · entry 2 Frohlich Mark W · CIK 0001420482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2035-05-23 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001931 · form4.xml · nonDerivative · entry 1 Frohlich Mark W · CIK 0001420482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:42 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $19.70 | $0.00 |
DisclosureSEC source: 0000905148-25-000899 · form4.xml · derivative · entry 1 Frohlich Mark W · CIK 0001420482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2035-03-06 F1 · derivative.exercise_date: The option shall vest in equal monthly installments over a period beginning on March 6, 2025 and ending on the date of the annual meeting at which the Reporting Person is first scheduled to be considered for election by the stockholders, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.